Quick Search 
Drugs of the Future
Register or sign in

Volume 30, Issue 7, July 2005, Pages 673-757
 AERx® iDMS.
Treatment of type 1 and type 2 diabetes.
Sorbera, L.A., Leeson, P.A., Bayes, M.
Drugs Fut 2005, 30(7): 673
Summary | Full Text: HTMLPDF 
Kim, Y.C., Yoo, M., Lee, M.G.
Drugs Fut 2005, 30(7): 678
Summary | Full Text: HTMLPDF 
Humanized anti-CD22 Mab, Non-Hodgkin's lymphoma therapy, Treatment of systemic lupus erythematosus, Treatment of Sjögren's syndrome.
Davies, S.L., Martin, L.
Drugs Fut 2005, 30(7): 683
Summary | Full Text: HTMLPDF 
Leukemia therapy, Retinoid RARα agonist.
Davies, S.L., Castaner, J., Garcia-Capdevila, L.
Drugs Fut 2005, 30(7): 688
Summary | Full Text: HTMLPDF 
 Antiangiogenic therapy in cancer.
Donate, F.
Drugs Fut 2005, 30(7): 695
Summary | Full Text: HTMLPDF 
 Apoptosis-based therapies for hematological malignancies.
Petronelli, A., Riccioni, R., Pasquini, L., Petrucci, E., Testa, U.
Drugs Fut 2005, 30(7): 707
Summary | Full Text: HTMLPDF 
 Phosphodiesterase type 5 (PDE5) inhibition and cognitive enhancement.
Devan, B.D., Duffy, K.B., Bowker, J.L., Bharati, I.S., Nelson, C.M., Daffin, L.W. Jr., Spangler, E.L., Ingram, D.K.
Drugs Fut 2005, 30(7): 725
Summary | Full Text: HTMLPDF 
 Second-generation epothilones: discovery of fludelone and its extraordinary antitumor properties.
Cho, Y.S., Wu, K.-D., Moore, M.A.S., Chou, T.-C., Danishefsky, S.J.
Drugs Fut 2005, 30(7): 737
Summary | Full Text: HTMLPDF 
 The pharmacological actions of cannabidiol.
Long, L.E., Malone, D.T., Taylor, D.A.
Drugs Fut 2005, 30(7): 747
Summary | Full Text: HTMLPDF 
Short Communication
 Is tumor necrosis factor-α-converting enzyme (TACE) a therapeutic target for neuroprotection?.
X. Wang
Drugs Fut 2005, 30(7): 755
Full Text: HTMLPDF 

© 2020 Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy